CRO連續反彈,龍頭Q3淨利激增兩倍,機構剖析五大投資主線
10月以來,沉寂了一年多的醫藥板塊終於開啓反彈之旅!
自10月11日見底,以CRO指數爲例,短短12個交易日,該指數累計漲幅近16%。
而當下正值三季報密集披露期,已有多家藥企披露三季報、或三季度業績快報/預告,行業整體業績較好。其中,藥明康德公告稱,第三季度淨利潤27.4億元,同比增長209%。
截至目前,A股共18家藥企在前三季度實現營收、淨利同比雙增,且淨利潤增幅超30%,新冠相關、醫療器械、原料藥等細分行業的公司居多。
醫藥行情能否持續?成了投資者目前的關注重點。
國盛證券發佈研報稱,近期醫藥行情反映加倉效應非常劇烈,按照近期成交額計算,全基這段時間加倉醫藥可能增加2-3%持倉水平,綜合考慮各方面,該機構認爲還有加倉空間,這次醫藥上漲邏輯是市場對於醫藥政策過分悲觀認知預期下的理性修復,這是一個會持續很長時間的事情。
從估值角度看,中泰證券研報認爲,CRO板塊已持續回調5個季度,估值收縮至歷史低位,進入適配區間。 其表示,CRO板塊作爲長坡厚雪的優質賽道,一體化平臺“前端導流+後端延伸”商業模式加速收穫,持續看好。
具體投資主線上,其建議關注五大主線:
1)疫情後時代持續恢復及前端項目導流有望帶來加速成長的臨牀CRO:泰格醫藥等;
2)性價比較高的“端到端、一體化”綜合型CRO、CDMO:藥明生物、藥明康德、康龍化成等;
3)特色細分賽道頭部公司:昭衍新藥、藥石科技等;
4)不斷快速成長或底部反轉的“小而美”標的:美迪西、成都先導等;
5)伴隨大訂單及後端項目加速延伸的頭部CDMO:凱萊英、博騰股份等。
來源:騰訊自選股
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.